Benefits
BV cure adjunct to metronidazole (Anukam PMID 16697231)
Anukam 2006 — 125 premenopausal BV women received oral metronidazole 500 mg BID days 1-7 + GR-1+RC-14 (1×10^9 CFU each) BID days 1-30 vs placebo. 88% cured (probiotic) vs 40% (placebo) at day 30 (P<0.001). Foundational pivotal evidence — substantial absolute cure-rate increase via probiotic adjunct.
Healthy women vaginal flora restoration (Reid 2003 PMID 12628548)
64 healthy women given oral GR-1 + L. fermentum RC-14 (now reclassified as L. reuteri RC-14) for 60 days. Microscopy showed 37% restoration from asymptomatic BV microflora to normal lactobacilli colonized state vs 13% placebo (P=0.02). Significant lactobacilli increase + yeast depletion + coliform reduction. Foundational asymptomatic dysbiosis evidence.
HIV-women trial cure rate negative (PMID 20801446)
Hummelen 2010 — 65 HIV-infected women with aberrant vaginal microbiota (Nugent 4-10) randomized to daily probiotic vs placebo for 6 MONTHS. BV (Nugent 7-10) received concurrent metronidazole. NEGATIVE primary: NO enhanced cure rate of BV with adjunct. Intermediate flora subgroup: probability of beneficial vaginal pH increased (OR 3.8, P=0.02). HONEST mixed evidence.
Chinese cohort BV adjunct NEGATIVE (PMC8291149 2021)
Zhang 2021 (Front Cell Infect Microbiol, doi:10.3389/fcimb.2021.669901) — Chinese cohort prospective parallel RCT of GR-1 + RC-14 as adjunct to BV treatment. RESULT: did NOT increase cure rate. Important honest counter-evidence — efficacy may be population/cohort-dependent. Reclassified taxonomy: Lacticaseibacillus rhamnosus + Limosilactobacillus reuteri.
Pregnancy vaginal microbiota safety (Yang 2020 PMC7071157)
Yang S, Reid G, Challis JR et al. 2020 (Nutrients 12:368, doi:10.3390/nu12020368) — pregnant women trial. 2.5×10^9 each GR-1+RC-14 capsules (Chr Hansen Denmark, gelatin capsules + dextrose + potato starch + microcrystalline cellulose + magnesium stearate). Vaginal microbiota + cytokine + chemokine outcomes. Foundational pregnancy safety + efficacy evidence.
Vaginitis 348-women treatment satisfaction
Cheng et al. — first large-scale 348-woman investigation of GR-1+RC-14 oral supplementation for 28 days WITHOUT antibiotics. >90% satisfied with treatment improvement in 10 vaginitis symptoms. No safety issues. Important antibiotic-free monotherapy evidence — vs adjunct-to-antibiotic context.
Lactic acid + H2O2 + bacteriocin antimicrobial
Lactobacillus dominance protects vaginal environment via D/L-lactate, H2O2, bacteriocins. Lactic acid acidifies via glycogen fermentation maintaining low vaginal pH (≤4.5). Lactic acid significantly positively correlated with Lactobacilli numbers. Foundational vaginal protection mechanism.
Mechanism of action
Lactic acid + low vaginal pH maintenance
Glycogen fermentation produces D/L-lactate maintaining vaginal pH ≤4.5. Mechanism: foundational vaginal protection against pathogen invasion.
H2O2 antimicrobial production
Hydrogen peroxide production inhibits anaerobic pathogens including Gardnerella, Mobiluncus, Prevotella associated with BV. Foundational antimicrobial mechanism.
Bacteriocin secretion
Bacteriocin production targets pathogenic bacteria via direct antimicrobial activity. Mechanism: complementing pH + H2O2 effects.
Oral-vaginal axis (translocation)
Oral capsule administration → vaginal niche colonization via gut-vaginal axis translocation. Distinguishing pharmacokinetic mechanism vs vaginal probiotic delivery.
Lactobacilli niche restoration
Reid 2003: 37% restoration to normal lactobacilli flora (vs 13% placebo) supports niche occupation mechanism. Distinguishes from suppressive antimicrobial approaches.
Cytokine/chemokine modulation (pregnancy)
Yang 2020 — vaginal microbiota + cytokine + chemokine modulation in pregnancy. Mechanism: immune modulation supporting normal pregnancy maintenance.
Clinical trials
Randomized double-blind placebo-controlled trial (PMID 16697231).
125 premenopausal women diagnosed with BV (vaginal irritation + discharge + 'fishy' odor + Nugent criteria + sialidase enzyme detection). All received oral metronidazole 500mg BID days 1-7. Randomized to oral GR-1 (1×10^9) + RC-14 (1×10^9) BID days 1-30 OR placebo. 106 returned for day-30 follow-up.
88% cured (antibiotic+probiotic group) vs 40% (antibiotic+placebo group) at day 30 (P<0.001). Of remaining: 30% placebo had BV vs 0% probiotic; 30% placebo intermediate vs 12% probiotic. Foundational pivotal evidence — substantial absolute cure-rate increase via probiotic adjunct.
Randomized placebo-controlled trial (PMID 12628548).
64 healthy women given daily oral capsules of L. rhamnosus GR-1 + L. fermentum RC-14 (since reclassified to L. reuteri RC-14) for 60 days vs placebo.
Microscopy: 37% restoration from asymptomatic BV microflora to normal lactobacilli colonized state vs 13% placebo (P=0.02). Lactobacilli detected in more women in probiotic group at day 28 (P=0.08) + day 60 (P=0.05). Significant lactobacilli increase + yeast depletion (day 28) + coliform reduction (days 28, 60, 90). NO adverse effects. Foundational asymptomatic dysbiosis evidence.
Randomized double-blind placebo-controlled trial (PMID 20801446).
65 HIV-infected women with aberrant vaginal microbiota (Nugent score 4-10). Daily probiotic vs placebo for 6 MONTHS. BV (Nugent 7-10) additionally received metronidazole 400mg BID for 10 days.
NEGATIVE PRIMARY OUTCOME: NO enhanced cure rate of BV among HIV women with adjunct probiotic to metronidazole. Intermediate flora subgroup (Nugent 4-6): probiotic increased probability of beneficial vaginal pH (OR 3.8, P=0.02); tendency toward normal vaginal flora (OR 2.4, P=0.1). HONEST framing — population-specific NEGATIVE result for primary BV cure outcome.
About this ingredient
LACTOBACILLUS RHAMNOSUS GR-1 + LACTOBACILLUS REUTERI RC-14 (recently reclassified as LACTICASEIBACILLUS RHAMNOSUS GR-1 + LIMOSILACTOBACILLUS REUTERI RC-14) is a specific STRAIN PAIR developed by REID + BRUCE LABORATORIES at University of Western Ontario — commercialized as FEMDOPHILUS / JARRO-DOPHILUS EPS by JARROW FORMULAS using strains supplied by CHR HANSEN (Denmark). Reclassification context: original Reid 2003 trial used L. fermentum RC-14, since reclassified to L. reuteri RC-14. PIVOTAL CLINICAL EVIDENCE: ANUKAM 2006 PMID 16697231 — 125 premenopausal BV women received oral METRONIDAZOLE 500mg BID days 1-7 + GR-1+RC-14 (1×10^9 each) BID days 1-30 vs placebo. RESULTS: 88% cured probiotic vs 40% placebo at day 30 (P<0.001). 30% placebo had BV vs 0% probiotic. 30% placebo intermediate vs 12% probiotic. REID 2003 PMID 12628548 — 64 healthy women × 60 days: 37% restoration to normal lactobacilli flora vs 13% placebo (P=0.02). Significant lactobacilli increase + yeast depletion + coliform reduction. HUMMELEN 2010 PMID 20801446 — 65 HIV-women 6-month NEGATIVE primary BV cure rate enhancement; intermediate flora subgroup beneficial vaginal pH (OR 3.8, P=0.02). ZHANG 2021 PMC8291149 (doi:10.3389/fcimb.2021.669901) — Chinese cohort prospective parallel RCT NEGATIVE — adjunct did NOT increase BV cure rate. YANG 2020 PMC7071157 (Nutrients 12:368) — pregnancy trial 2.5×10^9 each strain Chr Hansen capsules, vaginal microbiota + cytokine outcomes. CHENG et al. — 348-woman vaginitis 28-day antibiotic-free monotherapy >90% satisfaction.
MECHANISMS: LACTIC ACID + low vaginal pH ≤4.5 (glycogen fermentation — foundational vaginal protection); H2O2 antimicrobial production (Gardnerella/Mobiluncus/Prevotella inhibition); BACTERIOCIN secretion; ORAL-VAGINAL AXIS translocation (oral capsule → vaginal niche); LACTOBACILLI NICHE RESTORATION (Reid 2003 37% vs 13% placebo); CYTOKINE/CHEMOKINE modulation in pregnancy (Yang 2020). EVIDENCE: 3/5 reflects: (1) ANUKAM 2006 PIVOTAL 125-pt BV adjunct RCT (88% vs 40% cure), (2) REID 2003 64-pt 60-day healthy women asymptomatic dysbiosis RCT, (3) HUMMELEN 2010 65-pt HIV 6-month NEGATIVE primary outcome (HONEST framing — population-specific), (4) ZHANG 2021 Chinese cohort NEGATIVE (HONEST cohort-dependent efficacy), (5) YANG 2020 pregnancy safety + efficacy evidence, (6) CHENG 348-pt antibiotic-free vaginitis monotherapy, (7) WELL-CHARACTERIZED lactic acid + H2O2 + bacteriocin + niche restoration mechanisms, (8) RECLASSIFICATION TAXONOMY (L. fermentum RC-14 → L. reuteri RC-14; → Limosilactobacillus reuteri), (9) CHR HANSEN industry context warrants caveat but multi-investigator international research base, (10) higher-evidence than typical Lactobacillus probiotic for BV applications due to dedicated Reid+Bruce research program. SAFETY: Excellent — multiple multi-month trials including pregnancy safety + 348-pt monotherapy + HIV-women 6-month exposure. Best positioned as: (a) BV ADJUNCT to metronidazole therapy (Anukam 2006 88% cure rate evidence), (b) ASYMPTOMATIC DYSBIOSIS management in healthy women (Reid 2003 evidence), (c) PREGNANCY VAGINAL MICROBIOTA support (Yang 2020 safety), (d) ANTIBIOTIC-FREE VAGINITIS management (Cheng 348-pt evidence), (e) FEMDOPHILUS / JARRO-DOPHILUS EPS branded preparation preferable for strain match, (f) HIV-WOMEN: NEGATIVE primary BV cure outcome but possible intermediate-flora benefit, (g) CHINESE COHORT: NEGATIVE — efficacy may be population-dependent, (h) PREGNANCY: TESTED in pregnant women (distinguishing safety record), (i) IMMUNOCOMPROMISED: caution, (j) higher-evidence than typical Lactobacillus probiotic for women's urogenital health. Honest framing: GR-1+RC-14 has PIVOTAL Anukam 2006 evidence (88% vs 40% BV cure rate) but with HONEST counter-evidence — Hummelen 2010 HIV-women + Zhang 2021 Chinese cohort BOTH showed NEGATIVE primary outcomes. Efficacy may be population-dependent. Reclassification (L. fermentum RC-14 → L. reuteri RC-14 → Limosilactobacillus reuteri) reflects taxonomic update — but original Reid+Bruce strain identity preserved. Femdophilus / Jarro-Dophilus EPS branded (Jarrow Formulas, Chr Hansen-supplied) supports strain-matched supplementation. Yang 2020 pregnancy safety (Chr Hansen formulation) is distinguishing reproductive women's health context. Reasonable BV adjunct to metronidazole + asymptomatic dysbiosis management based on Anukam 2006 + Reid 2003 evidence — particularly compelling for non-HIV non-Chinese-cohort populations. HONEST: efficacy is NOT universal — counter-evidence in specific populations warrants caveat. Distinguishing among probiotics for unique reproductive women's health indication.